A continuing medical education session at the Society of Gynecologic Oncology’s 2018 Annual Meeting on Women’s Cancer offered insight for optimal selection and administration of PARP inhibitors, as well as homologous recombination deficiency testing in ovarian cancer. READ MORE
The US Preventive Services Task Force advises against ovarian cancer screening in asymptomatic women not known to be at high risk, concluding that the potential harms of screening outweigh the benefits.
A study soon to published found that palliative care for patients with ovarian cancer was often provided later than recommended in national guidelines.
Human epidermal growth factor receptor 2 may be a potential marker of poor prognosis in patients with unclassified ovarian cancer, according to a recent meta-analysis.
Researchers have developed an algorithm for differentiating between healthy women and those with ovarian cancer, as well as differentiating BRCA1 mutated-disease from wild-type disease.